Novel modalities such as adeno-associated virus (AAV), lentiviral vectors (LVV), and plasmid DNA (pDNA) are gaining prominence with clinical experience and commercialized treatments. A key barrier in bioprocessing of such complex molecules is in the downstream chromatography step where improving process recoveries and efficiencies remain top priorities. Could we leverage well-established, traditional chromatography steps using chemistries such as ion exchange (IEX) to de-bottleneck and streamline the purification of these newer therapies? Learn how to implement chromatographic techniques using resin or membrane formats in your viral vector or pDNA processes.
In this webinar, you will learn:
- Insights into AAV, LVV, and pDNA process flows and manufacturing challenges
- Compatibility of implementing IEX chromatography in downstream bioprocessing and alternatives to affinity chromatography
- Data-driven case studies on the performance of Natrix®, Eshmuno®, and Fractogel® family of resins in downstream purification
Speaker
Ratish Krishnan
Merck
Senior Strategy Consultant
Ratish Krishnan is a senior strategy consultant in novel modalities bioprocessing. He has nearly 15 years of bioprocessing experience in vaccine, monoclonal antibodies, and viral vector modalities from pre-clinical to late-stage process characterization, validation, and commercialization activities. Ratish has led process development teams at Novartis and Pfizer prior to his current role where he serves as a global subject matter expert for viral vector manufacturing and provides strategic guidance to stakeholders and key customers. He is active in thought leadership activities at scientific conferences, technical webinars, and key authorship contributions in peer-reviewed articles.
Pharma and biopharma manufacturing
- Downstream Processing
Duration:1h
Language:English
Session 1:presented April 14, 2022
To continue reading please sign in or create an account.
Don't Have An Account?